Journal of Clinical Oncology, Vol 16, 434-440, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer

B Glimelius, T Linne, K Hoffman, L Larsson, JH Svensson, P Nasman, B Svensson and C Helmers
Department of Oncology, Uppsala, Sweden. Bengt.Glimelius@onkologi.uu.se

PURPOSE: The possibility that epoetin beta (EPO) could increase hemoglobin (B-Hb) levels and improve quality of life (QoL) in patients with advanced gastrointestinal cancers was investigated. PATIENTS AND METHODS: One hundred patients with gastric, pancreatic, biliary, or colorectal cancers and subnormal B-Hb levels were included in a randomized study to test low-dose EPO (2,000 U subcutaneously thrice weekly [2,000 group]) against a higher dose (10,000 U times three [10,000 group]). Eighty-four patients were treated with chemotherapy. QoL was evaluated using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 instrument. RESULTS: At baseline, mean B-Hb was 108 g/L with no difference between the groups. In the 10,000 group, an increase in B-Hb (>10 g/L) was seen in 30 (73%) patients treated with chemotherapy, after a median of 4 weeks, whereas a corresponding increase in the 2,000 group was seen in 15 (30%) patients after a median of 10 weeks (P < .001). A difference in the proportion of responders (five of eight v one of eight) was also seen in the group of patients not treated with chemotherapy. The proportion of responders was independent of baseline endogenous serum EPO level or observed/predicted log10 serum (S)-EPO levels. Patients who demonstrated improved B-Hb levels also showed improvements in QoL parameters. Tumor response was usually also associated with QoL improvements. CONCLUSION: Treatment with EPO at a dose of 10,000 U thrice weekly can rapidly and safely increase B-Hb levels in a high proportion of patients with advanced gastrointestinal cancers. QoL is influenced by the B-Hb increase, but also by the course of the underlying malignancy. It is therefore difficult to define clearly the clinical relevance of the B-Hb increase as such.

This article has been cited by other articles:

				A. I. Sarela, S. Yelluri, and for the Leeds Upper Gastrointestinal Cancer Multid Gastric Adenocarcinoma With Distant Metastasis: Is Gastrectomy Necessary? Arch Surg, February 1, 2007; 142(2): 143 - 149. [Abstract] [Full Text] [PDF]

				A. Osterborg, Y. Brandberg, V. Molostova, G. Iosava, K. Abdulkadyrov, M. Hedenus, and D. Messinger Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies J. Clin. Oncol., May 15, 2002; 20(10): 2486 - 2494. [Abstract] [Full Text] [PDF]

				C.-H. Kohne, D. Cunningham, F. Di Costanzo, B. Glimelius, G. Blijham, E. Aranda, W. Scheithauer, P. Rougier, M. Palmer, J. Wils, et al. Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients Ann. Onc., February 20, 2002; 13(2): 308 - 317. [Abstract] [Full Text] [PDF]

				L. D. Mastro and M. Venturini Strategies for the Use of Epoetin Alfa in Breast Cancer Patients Oncologist, October 1, 1998; 3(5): 314 - 318. [Abstract] [Full Text]